Valeant Pharmaceuticals Starts Phase 2 Retigabine Study For Treatment Of Postherpetic Neuralgia (Medical News Today)
Valeant Pharmaceuticals International (NYSE:VRX) announced that it has enrolled the first patient in its Phase 2 clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. [click link for full article]
Original post by Yahoo! News Search Results for shingles